Development of a Novel Cell-Permeable Protein–Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1
Open Access
- 24 December 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (1) , 822-831
Abstract
Polo-like kinase 1 (PLK1) is a key regulator of mitosis and a recognized drug target for cancer therapy. Inhibiting the polo-box domain of PLK1 offers potential advantages of increased selectivity and subsequently reduced toxicity compared with targeting the kinase domain. However, many if not all existing polo-box domain inhibitors have been shown to be unsuitable for further development. In this paper, we describe a novel compound series, which inhibits the protein–protein interactions of PLK1 via the polo-box domain. We combine high throughput screening with molecular modeling and computer-aided design, synthetic chemistry, and cell biology to address some of the common problems with protein–protein interaction inhibitors, such as solubility and potency. We use molecular modeling to improve the solubility of a hit series with initially poor physicochemical properties, enabling biophysical and biochemical characterization. We isolate and characterize enantiomers to improve potency and demonstrate on-target activity in both cell-free and cell-based assays, entirely consistent with the proposed binding model. The resulting compound series represents a promising starting point for further progression along the drug discovery pipeline and a new tool compound to study kinase-independent PLK functions.Keywords
Funding Information
- Engineering and Physical Sciences Research Council
- Medical Research Council (MC_UU_12022/1, MC_UU_12022/8, ML/L007266/1)
- European Commission
- Wellcome
- Biotechnology and Biological Sciences Research Council
- Cancer Research UK
This publication has 47 references indexed in Scilit:
- Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agentsF1000Research, 2017
- Plk1 Inhibitors in Cancer Therapy: From Laboratory to ClinicsMolecular Cancer Therapeutics, 2016
- Recent Advances and New Strategies in Targeting Plk1 for Anticancer TherapyTrends in Pharmacological Sciences, 2015
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyLeukemia, 2014
- Computational Analysis of Phosphopeptide Binding to the Polo-Box Domain of the Mitotic Kinase PLK1 Using Molecular Dynamics SimulationPLOS Computational Biology, 2010
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cellsBlood, 2009
- Targeting polo-like kinase 1 for cancer therapyNature Reviews Cancer, 2006
- Normal Cells, but Not Cancer Cells, Survive Severe Plk1 DepletionMolecular and Cellular Biology, 2006
- Polo-like kinases and oncogenesisOncogene, 2005
- The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box DomainCell, 2003